Company Overview
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.28.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +176.03% |
| 6 Months: | +56.55% |
| 3 Months: | +26.92% |
| 1 Month: | +32.05% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)60.66 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BCAX Bicara Therapeutics Inc. R2K | 28.10 | -10.14 | $1.85B | 0.00% | -38.70% | -32.34% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | 41.79M | 32.02M | 40.68M | 41.12M | 60.24M |
| Operating Income | - | - | -9.53M | -15.37M | -19.75M | -20.63M | -41.79M | -32.02M | -40.68M | -41.12M | -60.24M |
| EBITDA | - | - | - | - | - | - | -41.77M | -32.00M | -40.65M | -41.08M | -60.20M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | -36.77M | -27.34M | -36.29M | -37.33M | -56.16M |
| Tax Provision | - | - | - | - | - | - | 72.00K | 52.00K | 40.00K | 53.00K | 52.00K |
| Net Income | -7.41M | -9.29M | -22.84M | -12.51M | -17.05M | -17.48M | -36.85M | -27.39M | -36.33M | -37.39M | -56.21M |
| Diluted EPS | - | - | -38.23 | -18.94 | -19.01 | -1.60 | -0.68 | -0.50 | -0.67 | -0.68 | -0.93 |
| R&D Expense | - | - | 6.90M | 12.00M | 15.80M | 15.90M | 34.30M | 24.80M | 33.00M | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 37.66M | 39.89M | 82.39M | 155.60M |
| Operating Income | -37.66M | -39.89M | -82.39M | -155.60M |
| EBITDA | -37.72M | -39.87M | -82.33M | -155.50M |
| Interest Expense | 112.00K | 0 | - | - |
| Pretax Income | -37.84M | -51.98M | -67.81M | -137.73M |
| Tax Provision | 1.00K | 5.00K | 187.00K | 217.00K |
| Net Income | -37.84M | -51.98M | -68.00M | -137.95M |
| Diluted EPS | -2.45 | -1.53 | -4.05 | -2.52 |
| R&D Expense | - | 30.60M | 63.60M | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | 6.70M | 233.98M | 510.00M | 430.99M |
| Current Assets | 4.98M | 231.07M | 502.53M | 422.05M |
| Cash & Equivalents | 4.16M | 230.44M | 489.71M | 96.69M |
| Inventory | - | - | - | - |
| Receivables | - | - | - | - |
| Total Liabilities | 105.51M | 382.75M | 18.12M | 29.54M |
| Current Liabilities | 23.90M | 15.09M | 17.99M | 28.95M |
| Long Term Debt | - | - | - | - |
| Total Debt | 0 | 657.00K | 738.00K | 1.71M |
| Total Equity | -98.80M | -148.77M | 491.88M | 401.45M |
| Shares Outstanding | 51.76M | 51.76M | 54.44M | 56.60M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -32.08M | -45.63M | -74.75M | -106.83M |
| Investing Cash Flow | -192.00K | -586.00K | -9.00K | -318.45M |
| Financing Cash Flow | 31.70M | 272.50M | 334.03M | 32.26M |
| Capital Expenditure | -192.00K | -586.00K | -71.00K | -280.00K |
| Free Cash Flow | -32.27M | -46.21M | -74.82M | -107.11M |
| Net Change in Cash | -573.00K | 226.28M | 259.27M | -393.03M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 38.3% | 34.9% | -13.8% | -34.4% |
| ROCE % | 219.0% | -18.2% | -16.7% | -38.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 11.04% | 7.26M | $211.22M |
| 2 | T. Rowe Price Investment Management, Inc. | 10.05% | 6.61M | $192.29M |
| 3 | Siren, L.L.C. | 8.83% | 5.80M | $168.92M |
| 4 | Vestal Point Capital, LP | 8.26% | 5.42M | $157.92M |
| 5 | Deep Track Capital, Lp | 6.18% | 4.06M | $118.26M |
| 6 | Janus Henderson Group PLC | 5.08% | 3.34M | $97.20M |
| 7 | Red Tree Management, LLC | 4.83% | 3.17M | $92.29M |
| 8 | TPG GP A, LLC | 4.58% | 3.01M | $87.63M |
| 9 | Blackrock Inc. | 4.33% | 2.84M | $82.78M |
| 10 | Omega Fund Management, Llc | 3.64% | 2.39M | $69.64M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BCAX
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced it awar…
What Does the Bicara Therapeutics CEO's Sale of 15,000 Shares Mean for Investors?
This Boston-based biotech, focused on bifunctional antibody therapies for cancer, just reported a notable insider sale in recent filings.
Bicara (BCAX) Q4 2025 Earnings Transcript
Bicara Therapeutics is a clinical stage biotech company pioneering bifunctional antibodies for targeted tumor modulation. Founded in 2020, we've built a global team of over 100 employees headquartered in Boston with a clear focus on advanc…
Bicara Therapeutics ASCO Data Bolster Ficerafusp Alfa in Head and Neck Cancer
Bicara Therapeutics (NASDAQ:BCAX) said new data to be presented at the 2026 American Society of Clinical Oncology annual meeting support the clinical profile of ficerafusp alfa, also referred to by the company as Ficara, in first-line recur…
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a retrospective analysis of standard of care Phas…
A Look At Bicara Therapeutics (BCAX) Valuation After Recent Share Price Pullback
Recent trading performance and context Bicara Therapeutics (BCAX) has drawn investor attention after a choppy stretch in the stock, with shares down about 5% over the past day and roughly 16% over the past week. See our latest analysis for …
BCAX — Frequently Asked Questions
What is the current share price of Bicara Therapeutics Inc. (BCAX)?
As of 2026-07-14 21:23 PDT, Bicara Therapeutics Inc. (BCAX) trades at $28.10 on NasdaqGM. Its 52-week range is $9.99 to $30.40.
What is the market capitalisation of BCAX?
Bicara Therapeutics Inc. (BCAX) has a market capitalisation of $1.85B on NasdaqGM.
What is the P/E ratio of BCAX?
BCAX trades at a trailing price-to-earnings (P/E) ratio of -10.14. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 2.77.
What is the return on equity (ROE) of BCAX?
BCAX has a return on equity (ROE) of -32.34%. Its return on capital employed (ROCE) is -38.70%.
Is BCAX a good stock to buy?
This page provides a data-driven analysis of Bicara Therapeutics Inc. (BCAX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.